找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Isolated Liver Perfusion for Hepatic Tumors; Karl J. Oldhafer,Hauke Lang,Rudolf Pichlmayr Conference proceedings 1998 Springer-Verlag Berl

[復制鏈接]
樓主: Neogamist
21#
發(fā)表于 2025-3-25 04:02:42 | 只看該作者
22#
發(fā)表于 2025-3-25 08:09:40 | 只看該作者
Are There Indications for Intraarterial Hepatic Chemotherapy or Isolated Liver Perfusion? The Case oiver perfusion adds to IAHC an extracorporal extraction and allows the use of higher doses of chemotherapy. Its efficacy has been suggested in small phase II trials; however, its relative complexity and the lack of clear demonstration of its efficacy compared to the most recent and effective systemi
23#
發(fā)表于 2025-3-25 13:28:37 | 只看該作者
24#
發(fā)表于 2025-3-25 16:11:17 | 只看該作者
25#
發(fā)表于 2025-3-25 23:05:56 | 只看該作者
Percutaneous Isolated Liver Chemoperfusion for Treatment of Unresectable Malignant Liver Tumors: Tecix patients died early; one of necrotizing pancreatitis and the other of hepatic arterial thrombosis. Both deaths were related directly to the hepatic arterial catheter. Excluding these two deaths, the treatments were well tolerated. The major side effects were mild to moderate chemical hepatitis an
26#
發(fā)表于 2025-3-26 00:57:52 | 只看該作者
27#
發(fā)表于 2025-3-26 04:48:18 | 只看該作者
Isolated Hepatic Perfusion with Tumor Necrosis Factor , and Melphalan: Experimental Studies in Pigs cluding controls, as demonstrated by liver enzyme assays and histology. There was no significant hemodynamic, cardiopulmonary hemotological, or renal toxicity. In the phase I clinical study there was leakage in one patient (cumulative leakage 20%). There were three perioperative deaths (one possibly
28#
發(fā)表于 2025-3-26 10:48:34 | 只看該作者
29#
發(fā)表于 2025-3-26 13:28:27 | 只看該作者
30#
發(fā)表于 2025-3-26 19:38:26 | 只看該作者
Are There Indications for Intraarterial Hepatic Chemotherapy or Isolated Liver Perfusion? The Case os, when no resection is feasible, and when no active systemic chemotherapy is available. Liver metastases from colorectal cancer represent one of the best indications, and many trials have demonstrated that IAHC is an efficient treatment. Some of these trials were randomized and have demonstrated th
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-25 06:59
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
屏山县| 南昌市| 平利县| 达拉特旗| 翁源县| 保康县| 莱阳市| 芮城县| 琼结县| 新河县| 来宾市| 海宁市| 曲周县| 上高县| 宾阳县| 革吉县| 泰顺县| 桐城市| 吉安县| 新丰县| 兴业县| 贺兰县| 阳春市| 同心县| 尚义县| 佳木斯市| 封开县| 永安市| 祁阳县| 彭州市| 镶黄旗| 高邮市| 安吉县| 江源县| 万全县| 东兴市| 天长市| 静安区| 卓资县| 伽师县| 苍南县|